letter etc. with attested specimen signature of the duly authorized signatory(ies)

who are authorized to vote, to the Scrutinizer by e-mail to lakshmmi6@gmail.com with a copy marked to evoting@nsdl.

co.in.

2.

It is strongly recommended not to share your password with any other person and take utmost care to keep your password

confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password.

In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?”

option available on www.evoting.nsdl.com to reset the password.

3.

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for

Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800

22 44 30 or send a request to evoting@nsdl.co.in

28.

Other Instructions

1.

The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM,

thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM, a

consolidated Scrutinizer’s Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised

by him in writing, who shall countersign the same.

2.

The result declared along with the Scrutinizer’s Report shall be placed on the Company’s website www.apollohospitals.com

and on the website of NSDL https://www.evoting.nsdl.com immediately. The Company shall simultaneously forward the

results to the National Stock Exchange of India Limited and BSE Limited, where the shares of the Company are listed.:

letter of appointment of Shri. Som Mittal as an Independent Director setting out the terms and conditions would be

available for inspection without any fee by the members at the Registered Office of the Company during normal business hours on any

working day, excluding Saturday.

The Board is of the view that given his rich and varied experience, his association with the Company would be of immense benefit and

it is desirable to avail the services of Shri. Som Mittal as an Independent Director.:

Managing Director

None

Expertise in Specific

Functional areas

Hospitals Operations, Clinical Excellence,

Talent Management, Global Marketing,

International Business Development

Information Technology, Engineering,

Manufacturing and Automotive.

Qualification

Bachelor of Science degree from Stella

Maris College, Chennai

Post Graduate Degree in Public

Administration

Graduation from IIT Kanpur and Post-

Graduation from IIM, Ahmedabad

Experience

Smt. Preetha Reddy has over 30 years

experience in Healthcare Industry

Shri. Som Mittal has forty plus years of

global experience across diverse industries

(manufacturing, IT services, Engineering

and Automative)

Board Membership of other companies as on March 31, 2021

Public Limited Companies

1. Larsen & Toubro Limited, Independent

Director

2. Apollo Multi Speciality Hospitals Limited,

Director*

3. Imperial Hospital and Research Centre

Limited, Director*

4. Apollo Hospitals International Limited,

Director*

5. Lifetime Wellness Rx International

Limited, Director

6. Apollo CVHF Limited, Director*

7. Apollo Clinical Excellence Solutions

Limited, Director*

8. Apollo Reach Hospitals Enterprises

Limited, Director*

9. Indian Hospitals Corporation Limited,

Director

Public Limited Companies

1. Cyient Limited, Independent Director

2. Sheela Foam Limited, Independent

Director

3. Tata SIA Airlines Limited, Independent

Director:

message from the chairman . . . . . . . . .4

patient centric hospital network . .14

largest organised

pharmacy platform . . . . . . . . . . . . . . . .62

taking healthcare into

neighbourhoods . apollo health

and lifestyle limited . . . . . . . . . . . . . . .64

apollo 24/7 . placing care in

peoples’ palms . . . . . . . . . . . . . . . . . . . . .68

rising to the challenge of covid-19 . .72

Corporate Review

board members . . . . . . . . . . . . . . . . . . . .88

corporate information . . . . . . . . . . . . .89

directors’ report to the

shareholders . . . . . . . . . . . . . . . . . . . . . .90

corporate governance report . . . . .131

business responsibility &

sustainability report*

0 2

Statutory Section

auditors’ report on standalone

financial statements . . . . . . . . . . . . . .241

standalone financial statements . .250

statement pursuant to section 129

of the companies act, 2013 . . . . . . . . .333

auditors’ report on consolidated

financial statements . . . . . . . . . . . . . .336

consolidated financial statements . .344

0 4

Financial Statements

management discussion

and analysis . . . . . . . . . . . . . . . . . . . . . .167

clinical governance . . . . . . . . . . . . . .230

0 3

Business Review

* Business Responsibility Report is a separate enclosure and forms a part of this Annual Report.

Note: Patient names have been withheld from all case studies and patient testimonials in this report in order to protect patient privacy.:

Managing Director

Smt. Sangita Reddy

Joint: Managing

Managing Director, Shri. Krishnan Akhileswaran, Chief Financial Officer and Shri.S.M. Krishnan, Vice President-

Finance & Company Secretary. There has been no change in the Key Managerial Personnel during the year.

Board evaluation

Pursuant to the provisions of the Companies Act, 2013 and in terms of Regulation 17(10) of the SEBI Listing Regulations, the Board has

carried out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working

of the Committees. The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report.

remuneration poliCy

The Board has, on the recommendation of the Nomination & Remuneration Committee, approved a policy for selection and appointment

of Directors, Senior Management and their remuneration. The Remuneration Policy is stated in the Corporate Governance Report.

meetings of the Board

The Board met seven times during the financial year, the details of which are given in the Corporate Governance Report. The intervening

gap between the Meetings was within the period prescribed under the Companies Act, 2013.

risk management

The Board of Directors had constituted a Risk Management Committee to identify elements of risk in different areas of operations and

to develop a policy for actions associated to mitigate the risks. The Committee on a timely basis informed the members of the Board of

Directors about risk assessment and minimization procedures and in the opinion of the Committee there was no risk that may threaten

the existence of the Company. The details of the Risk Management Committee are included in the Corporate Governance Report.:

Managing Director

(Chairman CSR Committee).

Place : Chennai

Date : July 21, 2021:

Managing Director, Whole time director and/or Manager

(`in Million)

Sl.

Particulars of Remuneration

Name of the MD/WTD/Manager

Total

Amount

Dr. Prathap

C Reddy

Smt. Preetha

Reddy

Smt. Suneeta

Reddy

Smt. Shobana

Kamineni

Smt. Sangita

Reddy

1

Gross salary

(a) Salary as per provisions contained in

section 17(1) of the Income Tax. 1961.

57.48

29.12

29.12

29.12

29.12

173.96

(b) Value of perquisites u/s 17(2) of the

Income tax Act, 1961

-

-

-

-

-

-

(c ) Profits in lieu of salary under section

17(3) of the Income Tax Act, 1961

-

-

-

-

-

-

2

Stock option

NA

NA

NA

NA

NA

NA

3

Sweat Equity

NA

NA

NA

NA

NA

NA

4

Commission

as % of profit

-

-

-

-

-

-

others (specify)

-

-

-

-

-

-

5

Others, please specify

-

-

-

-

-

-

Total (A)

57.48

29.12

29.12

29.12

29.12

173.96

Ceiling as per the Act `176 million (being 10% of the net profits of the Company calculated as per Section 198 of the Companies Act, 2013)

B.

Remuneration to other directors

(`in Million)

Sl.

Particulars of Remuneration

Name of the Directors

Total

Amount

Shri.Vinayak

Chatterjee Dr.T. Rajgopal

Dr. Murali

Doraiswamy

Smt.Kavitha

Dutt

Shri.MBN

Rao

1

(a) Fee for attending board committee

meetings

0.80

1.10

0.80

1.00

1.60

5.30

(b) Commission

1.25

1.25

1.25

1.25

1.25

6.25

(c ) Others, please specify

-

-

-

-

Total (1)

2.05

2.35

2.05

2.25

2.85

11.55

Other Non Executive Directors

2

(a) Fee for attending

board committee meetings

(b) Commission

-

-

-

-

(c ) Others, please specify.

-

-

-

-

Total (2)

-

-

-

-

Total (B) = (1+2)

2.05

2.35

2.05

2.25

2.85

11.55

Total Managerial Remuneration

185.51

Overall Ceiling as per the Act `194 Million (being 11% of the net profits of the Company calculated as per Section 198 of the Companies Act, 2013:

Managing Director

36.45

50.00

4

Smt Shobana Kamineni, Executive Vice Chairperson

36.45

50.00

5

Smt Sangita Reddy, Joint: Managing Director

36.45

50.00

Total

217.65

285.00

Variable Bonus

Apart from the above mentioned base salaries, the Executive Directors are also eligible to receive a performance based annual bonuses

of upto 67.50% of their respective base salaries.

For all Executive Directors, excluding the Executive

Managing Director

36.45

29.12

4

Smt. Shobana Kamineni, Executive Vice Chairperson

36.45

29.12

5

Smt. Sangita Reddy, Joint: Managing

Managing Director will carry out the individual performance review based on the standard appraisal matrix and shall

take into account the appraisal score card and other factors mentioned hereinabove, whilst recommending the annual

increments and performance incentives to the N&R Committee for its review and approval.

e)

performance evaluation of the Board and the directors

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 of the Listing Regulations, Annual Performance Evaluation

was conducted for all Board Members as well as the with reference to working of the Board and its Committees.

This evaluation was led by the Chairman of the Nomination and Remuneration Committee with specific focus on the performance and

effective functioning of the Board. The Board evaluation framework has been designed in compliance with the requirements under the

Companies Act, 2013 and the Listing Regulations, and in consonance with the Guidance Note on Board Evaluation issued by SEBI. The

Board evaluation was conducted through a detailed questionnaire having qualitative parameters and feedback based on ratings.

Evaluation of the Board was based on criteria such as composition and role of the Board, Board communication and relationships,

functioning of Board Committees, review of performance and compensation to Executive Directors, succession planning, strategic

planning, etc.

Evaluation of Directors was based on criteria such as participation and contribution in Board and Committee meetings, representation of

shareholder interests and enhancing shareholder value, experience and expertise to provide feedback and guidance to top management

on business strategy, governance and risk, understanding of the organization’s strategy, risk and environment, etc.

The performance evaluation of the Chairman and the Executive Directors was carried out by the Independent Directors. The performance

evaluation of the Independent Directors was carried out by the entire Board. The Directors expressed their satisfaction with the overall

evaluation process.

f)

remuneration of directors

The details of the remuneration paid to the Directors for the year ended 31st March 2021 is given below:

(`in million)

Name of the Director

Remuneration paid for the year ended 31st March 2021

Total

Sitting Fee

Remuneration

Commission

Fixed Pay

Variable Pay

Dr. Prathap C Reddy

-

57.48

-

-

57.48

Smt. Preetha Reddy

-

29.12

-

-

29.12

Smt. Suneeta Reddy

-

29.12

-

-

29.12

Smt. Shobana Kamineni

-

29.12

-

-

29.12

Smt. Sangita Reddy

-

29.12

-

-

29.12

Shri. Vinayak Chatterjee

0.80

-

-

1.25

2.05

Dr. T. Rajgopal

1.10

-

-

1.25

2.35

Dr. Murali Doraiswamy

0.80

-

-

1.25

2.05

Smt. V. Kavitha Dutt

1.00

-

-

1.25

2.25

Shri. MBN Rao

1.60

-

-

1.25

2.85:

Managing Director Smt.Shobana Kamineni, Executive

Vice Chairperson and Smt.Sangita Reddy, Joint: Managing

Managing Director Smt.Shobana Kamineni, Executive

Vice Chairperson and Smt.Sangita Reddy, Joint: Managing Director, in line with the limits prescribed

under SEBI Listing Regulations.

b. Offer/Invitation to subscribe to NCDs on a private

placement basis

postal Ballots

The Company had sought the approval of shareholders through postal ballot for the following two special resolution(s):

Date of Postal

Ballot Notice

Description of Resolutions

Type of

Resolutions

No. of Votes

Polled

Votes cast in

favour

Votes cast

Against

2nd

December

2020

Approval of the proposal for capital raise through

issuance of securities by way of qualified institutional

placement(s) and/or preferential allotment(s)

Special

Resolution

118,453,681

118,451,533

2,148

27th

March 2021

Approval for the Scheme of Amalgamation between

Western Hospitals Corporation Private Limited

(Transferor Company – 01), Apollo Home Health care

(India) Limited (Transferor Company – 02) (hereinafter

referred to as Transferor Companies) and Apollo

Hospitals Enterprise Limited (Transferee Company)

and their respective members and creditors under

Section 233 of the Companies Act, 2013

Special

Resolution

120,175,720

120,174,048

1,672

Smt. Lakshmmi Subramanian, Company Secretary in Practice was appointed as scrutinizer for the above postal ballots. After receiving

the approval of the Board of Directors, Notice of the Postal Ballot, text of the Resolution and Explanatory Statement, relevant documents,

are sent to the shareholders to enable them to consider and vote for and against the proposal within a period of 30 days from the date

of dispatch.

E-voting facility is made available to all the shareholders and instructions for the same are specified under instructions for voting in the

Postal Ballot Notice. E-mails are sent to shareholders whose e-mail ids are available with the depositories and the Company along with

the Postal Ballot Notice. After the last day for receipt of ballots (e-voting), the Scrutinizer, after due verification, submits the results to

the

Managing Director which reviews the probability

of risk events that adversely affect the operations and profitability of the Company and suggests suitable measures to

mitigate such risks.

A Risk Management Framework is already in place and the Executive Management reports to the Board periodically on the

assessment and minimization of risks

h) proceeds of public, rights and preferential issues

During the year, the Company allotted 4,659,498 equity shares of `5/- each to Qualified Institutional Buyers (QIBs) on

23rd January 2021 under the Qualified Institutions Placement Scheme (QIP) at a price of `2,511/- per share including a

premium of `2,506/- per share.

The Audit Committee reviews the utilization of proceeds periodically.

i) management

The Management Discussion and Analysis Report is appended to this report.

j) Certificate from practicing Company secretary

A Certificate has been received from Smt. Lakshmmi Subramanian, Senior Partner of M/s. Lakshmmi Subramanian &

Associates, Practising Company Secretaries that none of the Directors on the Board have been debarred or disqualified

from being appointed or re-appointed as directors for the year ended 31st March 2021 by SEBI/Ministry of Corporate

Affairs or any such statutory body.

k) shareholders

1) Disclosures regarding appointment or re-appointment of Directors

As per the Companies Act, 2013, atleast two thirds of the Board should consist of retiring Directors, of which atleast

one third are required to retire every year.

Except the Chairman,: Managing

Managing Director

5. Reporting of the Internal Auditor

The Company has appointed Internal Auditors who report directly to the Audit Committee.

7.

Ceo/Cfo CertifiCation

The: Managing

Director's Relatives

1

1,000

0.00

(b-iv)

Employees

2

125

0.00

(b-v)

Hindu Undivided Families

969

55,242

0.04

(b-vi)

I E P F

1

431,489

0.30

(b-vii)

L L P

22

8,640

0.01

(b-viii)

Non Resident Indians

2,076

1,120,075

0.78

(b-xi)

Trusts

25

136,020

0.09

(b-x)

Unclaimed or Suspense Account

1

137,150

0.10

Sub-Total (B)(2)

66,173

8,781,572

6.11

(B)

Total Public Shareholding (B)= (B)

(1)+(B)(2)

67,067

100,783,009

70.09

Total (A)+(B)

67,090

143,658,011

99.91:

Managing Director of the Company, hereby declare that the Board of Directors have laid down a Code of Conduct for its

Board Members and Senior Management Personnel of the Company and they have affirmed compliance with the said code of conduct.

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place : Chennai

Suneeta Reddy

Date : June 23, 2021: Managing

letter dated 12th February 2021

b. We have examined the compliance of conditions of Corporate Governance by Apollo Hospitals Enterprise Limited (‘the Company’), for

the year ended 31st March 2021, as stipulated in the Regulations 17-27, clauses (b) to (i) of Regulation 46(2) and paragraphs C and

D of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), as amended,

pursuant to the Listing Agreement of the Company with the Stock Exchanges.

Management Responsibility

The compliance of conditions of Corporate Governance is the responsibility of the Management. This responsibility includes the design,

implementation and maintenance of internal control procedures to ensure the compliance with the conditions of Corporate Governance

stipulated in the SEBI Listing Regulations.

Auditor’s Responsibility

Our examination is limited to review of procedures and implementation thereof, adopted by the Company for ensuring the compliance of

the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied

with the conditions of Corporate Governance regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015, as amended.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness

with which the management has conducted the affairs of the Company.

For Lakshmmi Subramanian & Associates

Lakshmmi Subramanian

FCS: 3534

Place: Chennai

CP No: 1087

Date: June 23, 2021

UDIN: F003534C00042105:

Managing Director:

Managing Director:

Managing Director:

Managing Director:

letter

910

910

Pharmacy Income

12

54

Apollo Specialty Hospital Private

Limited

Revenue from Operations (Lab Tests)

18

14

Pharmacy Income

84

189

Commission on turnover

-

58

Reimbursement of expenses

-

31

Receivable as at year end

100

217

Corporate Guarantee/Comfort: letter

750

750

Apollo Bangalore Cradle Limited

Revenue from operations

-

25

Receivable at year end

-

65

Alliance Dental Care Limited

Share of revenue

49

74

Payable as at year end

15

8

Corporate Guarantee/Comfort letter

371

371

Apollo Dialysis Private Limited

Pharmacy income

-

0.15

Share of revenue

297

173

Payable at year end

16

17

Apollo Sugar Clinics Limited

Rental Income

13

12

Share of revenue from operations

95

100

Lab cost

62

109

Pharmacy income

23

12

IT Cost

1

1

Consultancy fee to doctors

1

2

Investigation Expenses

-

7

Payable as at year end

43

31

Apollo Nellore Hospitals Limited

Investments in equity

54

54

Rent

8

8

Lease deposit given

8

8

Payable as at year end

44

37

letter

1,295

1,295

Samudra Health Care Enterprise

Limited

Investments in equity

251

251

Revenue from operations

101

84

Reimbursement of expenses

12

1

Other receivable as at year end

14

34

Trade receivable as at year end

14

87

Western Hospitals Corporation

Private Limited

Investments In equity

154

154

Reimbursement of expense during the year

(Travel)

1

2

Loan o/s

134

137

Interest Income

13

12

Interest receivable

29

16

Other receivables as at year end

4

4

Sapien Bio Sciences Private Limited

Investments in equity

0.10

0.10

Investments in preference

26

26

Reimbursement expenses

2

Receivable as at year end

0.09

0.09

Assam Hospitals Limited

Investments In equity

743

739

Dividend received

-

4

Management Fees

20

26

Revenue from Operations

10

-

Interest expenses

16

-

Reimbursement of expense during the year

33

-

Other receivable as at year end

65

10

Trade receivable as at year end

10

20

Apollo Lavasa Health Corporation

Limited

Investments in equity

312

312

Reimbursement of expenses

10

2

Rent expenses

1

-

Departmental sales

-

0.03

Receivable as at year end

1

0.08

Apollo Rajshree Hospitals Private

Limited

Investments in equity

327

327

Reimbursement of expenses

7

0.26

Revenue from operations

174

130

Other receivable as at year end

87

-

Trade receivable as at year end

71

135

Corporate Guarantee/Comfort: Letter

300

60

Letter

70

20

Apollo Hospital International Limited

Investments in equity

480

480

Investments in preferences

110

110

Reimbursement of expenses

28

24

Revenue from operations

0.20

1

Other receivable as at year end

1

33

Trade receivable as at year end

7

37

Future Parking Private Limited

Investments in equity

24

24

Investments in preference

210

210

Rental Expenses for the year

29

29

Corporate Guarantee issued

35

35

Right-of-Use Asset

380

380

Lease liability

210

210

Payable as at year end

18

12

Medics International Lifesciences

Limited

Revenue from Operations

68

41

Reimbursement of expense during the year

17

-

Investments in equity

950

910

Investment made during the year

40

-

Interest receivable

-

12

Receivable as at year end

68

40

Apollo Pharmacies ltd

Sale of Pharmaceutical and other products

30,260

-

Receivable at year end

4,542

-

Brand License fee

167

-

Apollo Gleneagles Hospital Limited

Investments in equity

393

393

Revenue from operations

1,140

1,326

Reimbursement of expenses

75

42

Other receivable as at year end

148

74

Trade receivable as at year end

659

803

Commitment to contribute funds towards equity

4,100

-:

Managing Director:

Managing Director:

Managing Director:

Managing Director:

Managing Director:

Managing Director:

Letter of Credit

35

34

(c) Other money for which the Group is contingently liable

Customs Duty

372

310

Service Tax (Refer ii)

74

62

Provident Fund

39

22

Value Added Tax

5

1

Luxury Tax

3

3

Income Tax (Refer i & iii)

270

317

Other Matters

239

325

Total

9,676

8,941

Cotingent Assets

Consideration receivable as part of disposal of investment in associate

81

81

* Includes proportionate share of associate and joint venture companies

Notes

(i)

In respect of the company , relating to the proceedings pending before the relevant income tax authority for the assessment years 2009-10 to

2016-17, it is of the opinion that no additional provision for tax expense is considered necessary in the financial statements.

(ii)

In respect of the subsidiary company Imperial Hospital & Research Centre Limited (IHRCL) for Financial year 2006 – 2007 to 2010-2011, the

service tax department has raised a demand of `1.89 million which is disputed and the company has deposited a sum of `1.89 million under

protest against this demand. The company has filed an appeal against the said demand before CESTAT-Bengaluru, and the liability has been

considered contingent until the conclusion of the appeal.

(iii)

In respect of the subsidiary company Imperial Hospital & Research Centre Limited (IHRCL) for Assessment year 2007-2008, the income tax

department has raised a demand of `1.43 million which is disputed and appealed against by the Company. The company has deposited a sum

of `1.43 million under protest against this demand, pending disposal of its appeal. The liability will be considered contingent until the conclusion

of the appeal.

(iv)

In respect of Apollo Health & Lifestyle Limited, The Honourable supreme Court, has passed a decision on February 28, 2019 in relation to

inclusion of certain allowances in “Basic wages” for the purpose of determining contribution to provident fund under the Employees’ Provident

Funds & Miscellaneous Provisions Act, 1952. The Group is awaiting further clarifications from the judiciary/department in this matter in order

to reasonably asses the impact on its financial statements, if any. Accordingly, the applicability of the judgement to the group, with respect

to the period and the nature of allowances to be covered, and the resultant impact on the past provident fund liability, cannot be reasonably

ascertained, at present.

(v)

In respect of Apollo Health & Lifestyle Limited, the subsidiary company received an order from Provident Fund authorities regarding Provident

Fund (PF) payments on certain allowances given by the company to its employees for the period April 2014 to April 2016 aggregating to

`10 million excluding interest and penalties. The Parent Company has deposited a sum of `10 million under protest against this demand and

based on the legal opinion the demand has been considered as contingent in previous year. During the previous year the amount as per the

demand is fully provided for.:

Managing Director:

